Investing.com -- Grifols reported a 7.4% year-over-year jump in first-quarter revenues to €1.79 billion on Monday, driven by strong demand across its biopharmaceutical segment, which grew 6.6% at constant currency.
The Barcelona-based healthcare company posted adjusted EBITDA of €400 million, up 14.2% year-over-year, with a margin of 22.4%. Reported EBITDA rose 22.6% to €381 million. Group profit surged 179% to €60 million.
The company’s shares jumped 5% in European trading after the report.
Biopharma revenues reached €1.52 billion, buoyed by a 13.2% jump in immunoglobulin sales.
The company said albumin revenues declined 9.4% due to a temporary license renewal delay in China, which has now been resolved.
“Healthy underlying demand in Biopharma and across all parts of our business, coupled with strong operational execution, positions Grifols (BME:GRLS) for consistent growth throughout 2025,” said CEO Nacho Abia.
Diagnostics revenue rose 5.2% to €170 million, supported by Molecular Donor Screening (MDS) growth outside the U.S., joint business volume growth of Immunoassay and Blood Typing Solutions (BTS) expansion across Grifols’s core markets.
Grifols also reported a significant improvement in free cash flow, which improved by €209 million from a year earlier to minus €44 million, driven by better working capital management. .
“We remain focused on disciplined execution... and translating that strong growth into sustained improvement of free cash flow generation,” said CFO Rahul Srinivasan.
Grifols reaffirmed its 2025 financial guidance and expects to launch its fibrinogen therapy in Europe later this year, with a U.S. rollout expected in the first half of 2026.
Sam Boughedda contributed to this report.